Description

PRIMAQUINE 7.5 TABLET is an effective antimalarial medication that contains Primaquine Phosphate 7.5 mg, used primarily for the radical cure of P. vivax and P. ovale malaria. This formulation is particularly suitable for weight-based dosing, pediatric use, or dose titration in sensitive patients or populations requiring lower doses.

Primaquine acts against the liver-stage hypnozoites, which are dormant forms of malaria parasites responsible for recurring infections. It also has gametocytocidal activity against Plasmodium falciparum, helping to block the transmission of malaria in endemic regions.

• Radical cure of relapsing malaria (P. vivax, P. ovale)

• Transmission-blocking treatment in P. falciparum malaria

• Adjunct therapy in mass drug administration campaigns

• Pediatric or low-weight patient treatment protocols

• Targets dormant liver-stage parasites to prevent malaria relapse

• Supports public health malaria eradication strategies

• Available in lower-dose 7.5 mg format for tailored dosing

• Reduces risk of malaria transmission in endemic communities

• G6PD testing is essential prior to initiating therapy to prevent hemolytic anemia

• Use with caution in children, elderly, and patients with borderline G6PD levels

• Contraindicated during pregnancy and breastfeeding

• Always use under the guidance of a qualified healthcare provider

PRIMAQUINE 7.5 TABLET is produced by BLUEPILL EXPRESS, a global leader in third-party pharmaceutical manufacturing and exports. The product is manufactured under WHO-GMP, ISO-certified, and FDA-compliant facilities ensuring:

• International quality benchmarks

• Batch-to-batch consistency

• Stringent QC/QA protocols

• Scalable production for large-volume tenders

As a dedicated pharmaceutical exporter, BLUEPILL EXPRESS supplies antimalarial drugs such as PRIMAQUINE 7.5 TABLET to health ministries, NGOs, hospitals, and international procurement agencies in Africa, Latin America, Southeast Asia, and other malaria-endemic regions.

Our export model supports private labeling, custom packaging, and regulatory documentation tailored to the needs of each importing country.

• Administer orally with food to reduce GI side effects

• Dose is typically calculated based on body weight (e.g., 0.25–0.5 mg/kg daily for 14 days)

• Must be taken exactly as prescribed by a physician

• G6PD screening is mandatory before administration